March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Dexamethasone Intravitreal Implant (Ozurdex®) In Patients With Macular Edema Due To Retinal Vein Occlusion
Author Affiliations & Notes
  • Mathias M. Maier
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Thomas Groneberg
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Nikolaus Feucht
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Carsten H. Meyer
    Ophthalmology, Pallas Klinik,, Olten, Switzerland
  • Georg Spital
    Ophthalmology, St. Franziskus Hospital, Münster, Germany
  • Joachim Wachtlin
    Ophthalmology, Sankt-Gertrauden Krankenhaus, Berlin, Germany
  • Lars O. Hattenbach
    Ophthalmology, Augenklinik des Klinikums Ludwigshafen, Ludwigshafen, Germany
  • Nicolas Feltgen
    Ophthalmology, Universitätsmedizin Göttingen, Göttingen, Germany
  • Chris P. Lohmann
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Footnotes
    Commercial Relationships  Mathias M. Maier, None; Thomas Groneberg, None; Nikolaus Feucht, None; Carsten H. Meyer, None; Georg Spital, None; Joachim Wachtlin, None; Lars O. Hattenbach, None; Nicolas Feltgen, None; Chris P. Lohmann, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 920. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mathias M. Maier, Thomas Groneberg, Nikolaus Feucht, Carsten H. Meyer, Georg Spital, Joachim Wachtlin, Lars O. Hattenbach, Nicolas Feltgen, Chris P. Lohmann; Dexamethasone Intravitreal Implant (Ozurdex®) In Patients With Macular Edema Due To Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):920. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To asses the therapeutic effect of the dexamethasone implant (Ozurdex®) on macular edema in relation to duration in patients with retinal vein occlusion (RVO).

Methods: : In a clinical, non randomized, multicenter retrospective study 135 patients with vision loss owing to macular edema associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) were included.BCVA and CRT (measured by SD-OCT) at baseline and 3 months after injection of the dexamethasone implant (Ozurdex®) in patients suffering from macular edema after fresh RVO (0-12 weeks, n=35), intermediate RVO (13-39 weeks, n=51) and longstanding RVO (> 40 weeks, n=49) were compared.

Results: : There was no difference in BCVA at baseline between the groups (BCVA logMAR was 0,73 for fresh; 0,68 for intermediate and 0,81 for the longstanding group). There was significant and similar increase of BCVA for all groups (BCVA logMAR: fresh 0,18 p=0,004; intermediate 0,15 p=0,004; longstanding 0,21 p=0,000). We found a significant reduction in CRT for all groups. Reduction in CRT was more pronounced in patients with fresh and intermediate RVO (p=0,006, p=0,002), but CRT at baseline was significant less in longstanding RVO in comparison to fresh and intermediate RVO (p=0,015; p=0,010).

Conclusions: : In our study increase of BCVA seems to be independent of duration of RVO. A significant reduction in CRT was also found in patients with longstanding RVO.

Keywords: retina • vascular occlusion/vascular occlusive disease • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×